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Extensive Amplification and Self-Renewal of Human Primitive
Hematopoietic Stem Cells From Cord Blood
By Wanda Piacibello, Fiorella Sanavio, Lucia Garetto, Antonella Severino, Daniela Bergandi, Jessica Ferrario,
Franca Fagioli, Massimo Berger, and Massimo Aglietta
The use of umbilical cord blood as a source of marrow repop- ated (the number of colony-forming unit–granulocyte-mac-
ulating cells for the treatment of pediatric malignancies has rophage [CFU-GM] present at the end of 6 months of culture
been established. Given the general availability, the ease are well over 2,000,000-fold the CFU-GM present at the
of procurement, and progenitor content, cord blood is an beginning of the culture). Very primitive hematopoietic pro-
attractive alternative to bone marrow or growth factor mobi- genitors, including long-term culture-initiating cells (LTC-
lized peripheral blood cells as a source of transplantable ICs) and blast cell colony-forming units, are also greatly ex-
hematopoietic tissue. However, there is a major potential panded (after 20 weeks of liquid culture, LTC-IC number is
limitation to the widespread use of cord blood as a source over 200,000-fold the initial number). The extremely pro-
of hematopoietic stem cells for marrow replacement and longed maintenance and the massive expansion of these
gene therapy. There may be enough hematopoietic stem progenitors, which share many similarities with murine
cells to reconstitute children, but the ability to engraft an long-term repopulating cells, suggest that extensive re-
adult might require ex vivo manipulations. We describe an newal and little differentiation take place. This system might
in vitro system in which the growth of cord blood CD34" prove useful in diverse clinical settings involving treatment
cells is sustained and greatly expanded for more than 6 of grown-up children and adults with transplantation of nor-
months by the simple combination of two hematopoietic
mal or genetically manipulated hematopoietic stem cells.growth factors. Progenitors and cells belonging to all hema-
q 1997 by The American Society of Hematology.topoietic lineages are continuously and increasingly gener-
H culture-initiating cell assay (LTC-IC), which detects cellsthat can generate myeloid clonogenic cells (colony-formingEMATOPOIETIC tissues contain a small population ofprimitive, totipotent stem cells capable of self-renewal
and of generating committed progenitors of the different cells [CFCs]) in long-term cultures for a minimum of 5
weeks, appears to be useful in this regard.7 Indeed, humanmyeloid and lymphoid compartments.1-4 In the semisolid
assays, hematopoietic progenitors in the presence of specific LTC-ICs share a number of features with in vivo murine
long-term repopulating cells.8 A number of other assays havegrowth factors proliferate and differentiate to give origin to
mature cells.5 In this system, depending on the combination been advanced as potentially having some correlations with
long-term murine repopulating cells. These include assaysof growth factors, different classes of multipotent committed
progenitors (colony-forming units–granulocyte-macrophage for cobblestone areas colony-forming cells (CAFC),9 high
proliferative potential colony-forming cells (HPP-CFC),10[CFU-GM], burst-forming units-erythroid [BFU-E], and col-
ony-forming units-megakaryocyte [CFU-Mk]) with a high mixed colony-forming units granulocyte, erythroid, mono-
cyte, megakaryocyte (CFU-GEMM),11 and blast cell colony-differentiation but a negligible self-renewal capacity are
identified.1-6 forming units (CFU-Bl).12,13 The development of assays
suitable for the detection of human stem cells and their dis-Several culture systems to identify early progenitor/stem
cells have been described. In the human system, long-term tinction from other hematopoietic cells with more restricted
proliferative and differentiation potentials, therefore, has rep-
resented so far an important task. Many attempts to identify
culture conditions able to support a prolonged and significantFrom the Department of Biomedical Sciences and Human Oncol-
expansion of primitive stem cells have been disappointing,ogy, Clinical Section, Torino Medical School, University of Torino,
Torino, Italy; the Torino Medical School, University of Torino, He- despite considerable success with mature committed progen-
matology/Oncology, Ospedale Mauriziano, Torino, Italy; the Insti- itors. Indeed, although committed progenitor production can
tute for Cancer Research and Treatment (IRCC), Candiolo, Italy; be quite impressive, its sharp decline after some weeks sug-
and the Department of Pediatrics, Torino, Italy. gests that differentiation and not self-renewal predomi-
Submitted December 9, 1996; accepted January 27, 1997.
nates.14,15 These systems can, therefore, be very useful toSupport for this work was provided by grants from Associazione
expand the committed progenitor population and hopefullyItaliana per la Ricerca sul Cancro (AIRC; Milan, Italy) and Consig-
to shorten the early phase of cytopenia that follows bonelio Nazionale delle Ricerche (CNR; Rome, Italy) to special project
marrow16,17 or cord blood18-20 transplantation.ACRO (Grant No. 01062.PF399) to M.A. and from the Ministero
However, their usefulness appears more uncertain in thosedell’Universita` e della Ricerca Scientifica e Tecnologica to W.P.
and to M.A. L.G. and A.S. are recipients of the ‘‘G. Ghicotti Founda- situations, such as cord blood (CB) transplantation, in which
tion,’’ Ses. Piemonte grants. the limited number of stem cells seems to question its feasi-
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ica I, Department of Biomedical Sciences and Human Oncology, period of pancytopenia is frequent before graft taking.21
Via Genova 3, 10126 Torino, Italy. We describe here a stroma-free cell culture system in
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PRIMITIVE STEM CELL EXPANSION 2645
cells colony forming units (CFU-Cs) in methylcellulose mediumsion of hematopoietic progenitors (including LTC-IC and
containing 1.3% methylcellulose (Fluka Chemika Biochemika,CFU-Bl) suggest that extensive renewal, with a limited dif-
Buchs, Switzerland), 30% FCS, EPO (3 U/mL), IL-3 (20 ng/mL),ferentiation, take place. This system might prove very useful
G-CSF (20 ng/mL), GM-CSF (20 ng/mL), and KL (50 ng/mL).to expand primitive hematopoietic progenitor/stem cells and
These cultures were incubated at 377C and colonies were scored 2to widen the feasibility of cord blood transplantation.
to 3 weeks later. LTC-IC enumeration was based on the number of
CFU-C scored in the limiting dilution assays (LDA).
MATERIALS AND METHODS Stroma-free long-term cultures. Stroma-free long-term cultures
were performed as follows. Two to ten thousand CD34/ CB cellsCell Sources
were cultured in quadruplicate flat-bottomed 24-well plates in 1 mL
Bone marrow (BM) was obtained by aspiration from the posterior
of IMDM supplemented with 10% FCS and the following cytokines:iliac crest of fully informed hematologically normal donors. Umbili- IL-3 (10 ng/mL), IL-6 (10 ng/mL), KL (50 ng/mL), FL (50 ng/mL),
cal cord blood (CB) was obtained at the end of full-term deliveries,
and TPO (10 U/mL), which were added, alone or in a combination
after clamping and cutting of the cord by drainage of blood into
of two or more factors, to each series of microwells twice a week.
sterile collection tubes containing the anticoagulant citrate-phosphate The wells were grown at 377C.dextrose. At initiation of the culture, the number of CFU-GM present in 1
mL of a single well was determined by agar culture,30 the number
CD34/ Cell Purification of CFU-Mk by plasma-clot technique,31 and the number of BFU-E
and CFU-GEMM by methylcellulose assay.11 All the assays wereMononuclear cells (MNC) were isolated from CB using Ficoll
performed in quadruplicate.Hypaque (density, 1077; Nyegaard, Oslo, Norway) density centrifu-
Every week all the wells were demidepopulated by removal ofgation. Cells were subjected to two cycles of plastic adherence (60
one half the culture volume, which was replaced with fresh mediumminutes each); they were then were washed with Hanks’ Balanced
and growth factors. Cells of the harvested media were counted andSalt Solution (GIBCO BRL, Grand Island, NY).
suitable aliquots of the all suspension were assayed for CFU-GMThe CD34/ MNC fraction was isolated with superparamagnetic
and CFU-Mk every week and for BFU-E, for CFU-GEMM, formicrobeads selection using high-gradient magnetic field and mini-
CFU-Bl, for LTC-IC, and for immunophenotype analysis every 2MACS columns (Miltenyi Biotech, Glodbach, Germany).
or 3 weeks.The efficiency of the purification was verified by flow cytometry
The total number of CFU-GM, CFU-MK, BFU-E, and CFU-counterstaining with a CD34-phycoerythrin (PE; HPCA-2; Becton
GEMM present in each LTC well was determined by using theDickinson, Mountain View, CA) antibody. In the cell fraction con-
following equation: CFU-E or BFU-E per milliliter of culture  ytaining purified cells, the percentage of CD34/ cells ranged from
(observed CFU-C 1 2n), where n is the number of previous demide-90% to 98%.
populations31,32 and y is the number corresponding to the fraction of
1 mL cell suspension (ie, 1/62  15.6 mL and 1/34  mL) that wasRecombinant Human Cytokines
plated in semisolid assays.
The following recombinant purified human cytokines were used Clonogenic assays. The clonogenic assays were performed as
in these studies: recombinant human (rh) stem cell factor or c-kit follows. For CFU-GM, 5 1 102 CD34/ CB cells of the initial cell
ligand (rhKL) and recombinant human granulocyte colony-stimulat- suspension or aliquots of the stroma-free long-term cultures were
ing factor (rhG-CSF) were from Genzyme (Cambridge, MA); re- cultured at 4 plates per point in 3% agar, 15% FCS in IMDM
combinant human granulocyte-macrophage colony-stimulating fac- (GIBCO). For CFU-Mk, the same number of cells was cultured in
tor (rhGM-CSF), recombinant human interleukin-6 (rhIL-6), and plasma clot assay (4 dishes per point) as previously described.31,32
rhIL-3 were from Sandoz AG (Basel, Switzerland); recombinant For BFU-E and CFU-GEMM, 5 1 102 CD34/ CB cells/dish in at
human erythropoietin (rhEPO; EPREX) was from Cilag (Milan, It- least 4 plates per point were cultured in 1.3% methylcellulose
aly); recombinant human FLT3-ligand (rhFL) was obtained from (Fluka), 30% FCS in IMDM at 377C in a humidified atmosphere at
SD Lyman (Immunex Corp, Seattle, WA); rhTPO was obtained from 5% CO2 in air. Colony scoring was performed on day 12 for CFU-D.C. Foster (Zymogenetics, Seattle, WA); rhIL-7 and rhIL-12 were MK (at the immunofluorescent microscope after staining with a
from R&D Systems Inc (Minneapolis, MN). fluorescein isothiocyanate [FITC]-conjugated MoAb recognizing
GPIIbIIIa) and on day 14 for CFU-GM, BFU-E, and CFU-GEMM.
Progenitor Assays Several growth factors were added at optimum concentrations to
sustain the formation of BFU-E and CFU-GEMM: IL-3 (20 ng/mL),LTC-ICs. LTC-ICs were performed as follows. BM stroma was
GM-CSF (10 ng/mL), Epo (3 U/mL), and KL (50 ng/mL). For CFU-produced by culturing 107 fresh BM MNC in a T25 flask for at least
GM, G-CSF (20 ng/mL), GM-CSF (20 ng/mL), IL-3 (20 ng/mL),2 weeks in 5 mL stromal medium (12.5% horse serum [HS] and
and KL (50 ng/mL) were added. For CFU-MK, IL-3 (5 ng/mL) was12.5% fetal calf serum [FCS]; both from Hyclone [Logan, UT]),
added.Iscove’s modified Dulbecco’s medium (IMDM; GIBCO BRL), 2-
CFU-Bl. Blast cell colony assay was performed according tomercaptoethanol (Sigma, St Louis, MO), 1006 mol/L hydrocortisone
the method described by Leary and Ogawa13 by plating 1 1 103(Sigma), and penicillin/streptomycin. One or 2 days before cocul-
CD34/ CB cells of the initial purified population. IL-3 (10 ng/mL)tures, BM stroma was irradiated with 15 Gy and plated at 7 1 103/
and IL-6 (10 ng/mL) were added on day 14.cm2 in 24-well plates to form preestablished stromal layers for the
Colonies were scored after 7 to 10 days of incubation at 377C.long-term cultures. Limiting dilutions (1 to 1,000 CD34/ CB cells)
When identified, blast cell colonies containing 25 or more cells wereand equivalent aliquots (ie, limiting dilutions) of the cells grown in
replated in secondary cultures for confirmation of their ability tolong-term stroma-free cultures after 2 to 20 weeks were seeded on
form secondary colonies. For this purpose, blast cell colonies weretop of the irradiated BM stroma in culture medium containing
individually plucked from the culture and suspended in 100 mLIMDM, 12.5% HS, 12.5% FCS, 2-mercaptoethanol, and 1006 mol/
IMDM. The samples were gently pipetted to obtain a single cellL hydrocortisone for 5 weeks at 337C with weekly changes of half
suspension and then added to 0.9 mL of methylcellulose mediumthe medium. At the end of the 5-week LTC-IC assay period, nonad-
containing 30% FCS, 1% deionized bovine serum albumin (Sigma),herent cells were removed from the cultures, combined with the
corresponding trypsinized adherent cells, washed, and assayed for 3 U EPO, 20 ng/mL IL-3, 20 ng/mL GM-CSF, 20 ng/mL G-CSF,
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and 50 ng/mL KL. Cultures were incubated at 377C for 14 additional for more than 6 months (Fig 2A). The total cell counts were
days and all the colonies were enumerated. Smears were prepared performed weekly. In the cultures without cytokines, a rapid
using a cytospin for morphologic examinations. decrease in cell number was observed during the first 3
Every 2 to 3 weeks aliquots of the harvested liquid cultures were weeks and by day 21 no cells were alive. Cultures set up
assayed for CFU-Bl. Secondary replating was performed on at least
with either TPO or FL alone lasted, respectively, 4 and 1020 colonies, as described above.
weeks.Immunophenotyping by flow cytometry. After purification, ali-
By contrast, in the long-term cultures (LTC) containingquots of CD34/ CB cells were incubated with mouse IgG (Fluka)
the association of FL and TPO, a progressive, steady increaseto block nonspecific binding to Fc receptor and then stained with a
of cell production was seen. After 5 weeks the cell outputpanel of monoclonal antibodies (FITC- or PE-conjugated CD34,
CD38, CD33, CD14, CD2, CD19, and CD41 [all from Becton Dick- was greater than 1,000-fold the input number; after 15 weeks,
inson] and antiglycophorin [Dakopatts, Glostrup Denmark]). FITC- it was greater than 1,000,000-fold and at week 25 the cell
and PE-conjugated mouse isotype control antibodies were used for output was greater than 50,000,000-fold the input number.
each culture.
Every 2 to 3 weeks aliquots of cultured cells were counted,
Immunophenotype of Cultured Cellswashed, and then subjected to the same procedure. The only differ-
ence was that cells were also incubated with propidium iodide (1 Cells harvested weekly were assayed by flow cytometry
mg/mL) to analyze only viable cells. for surface antigen expression using essentially viable cells
Flow cytometric analysis was performed using a FACScan cyto- (Fig 2B). The CD34/ cell population, in the presence of FL
meter (Becton Dickinson). At least 10,000 events were acquired for / TPO kept increasing throughout the LTC period. After 5
each analysis.
weeks, CD34/ cells were close to 1,600-fold the initial value;
after 20 weeks, they reached 146,000-fold the initial valueRESULTS
and kept growing.In an effort to induce the long-term proliferation and, Previous studies have shown that CD34/ CD380 cellspossibly, the amplification of primitive hematopoietic pro-
constitute a small population of primitive hematopoietic stemgenitors contained in CD34/ CB cells, we set up stroma-
cells enriched for LTC-IC.46,47 We thus wanted to seefree suspension cultures in which a number of cytokines
whether this subpopulation persisted during the LTC period.known to be active on more immature hematopoietic progen- As shown in Fig 2B, the CD34/ CD380 subpopulation notitors (IL-3 and IL-6)14,15,33 in combination with early acting
only persisted, but underwent a continuous expansion. In-
cytokines (kit ligand or stem cell factor [KL]14,15,34-36 and deed, after 5 weeks of culture, it was 300-fold the inputFLT3 ligand [FL])22-24,37-41 were used. Although cellular pro-
value; at week 20, it was greater than 500,000-fold the inputliferation occurred (7,000- to 12,000-fold the input cell num-
number and kept expanding. The complete immunopheno-ber after 8 weeks of culture with IL-3 and KL or IL-3 and typing of cultured cells showed that the most of the cellsFL), by week 10 the total cell population began to decrease produced in LTC belonged to the granulocyte-macrophage,
and soon disappeared. Accordingly, the output of committed the erythroid, and the megakaryocyte lineages. CD2/ andprogenitors (CFU-C) after an initial increase (36-fold the CD19/ cells represented only 0.2% and 0.012% of the totalinput CFU-C after 8 weeks of culture) by week 10 progres-
cell population.
sively decreased (Fig 1A and B).
The addition of both KL and FL to IL-3 further enhanced
CFC Content and Amplification in LTCscell proliferation and CFU-C output, but, again, without sub-
stantial effects on the long-term maintenance of primitive To measure the progenitor content of the cell expansion
stem cells. occurring throughout the LTC, semisolid assays for CFU-
In contrast, KL plus FL, in the absence of IL-3 or in the GM and CFU-Mk were performed weekly and for BFU-E
presence of IL-6, enhanced progenitor cell proliferation to a and for CFU-GEMM were performed every 2 to 3 weeks.
much greater extent and for a longer time (after 12 to 14 Figure 2C shows the fold increase, over time, of CFU-GM,
weeks of culture, the cell output was 10,000- to 20,000- CFU-Mk, BFU-E, and CFU-GEMM generated during 6
fold the input value, and CFU-C output was greater than months of liquid cultures.
200- to 300-fold). However, at week 14, progenitor cell pro- After 5 weeks of culture, CFU-GM output was greater
liferation slowed down and by week 16 disappeared com- than 70-fold and by week 25 was greater than 6,000,000-
pletely (Fig 1A and B). fold the input value. Besides CFU-GM, during the entire
c-mpl ligand (TPO) is a likely growth factor also for primi- culture period, CFU-Mk, BFU-E, and CFU-GEMM were
tive stem cells26-29,42-45; therefore, we sought whether the generated by the expanded cells. Indeed, CFU-Mk generated
combination of TPO with another early acting cytokine after 15 weeks of culture were 1,000-fold the number of
would support the long-term proliferation and perhaps the CFU-Mk present in the inoculum at the beginning of the
renewal of primitive human CB hematopoietic stem cells. suspension cultures. After 25 weeks, they were well over
In an attempt to carefully investigate the proliferative 45,000-fold the input number. Similarly, BFU-E and CFU-
events occurring during the long-term cultures, different GEMM were generated during the entire culture period (at
stages of hematopoiesis were analyzed. week 15, they were, respectively, 9,000- and 850-fold;
at week 25, they were 122,000-fold and 27,000-fold the
CD34/ Cell Proliferation input number, respectively).
In an effort to show that, among the cells growing in theHighly purified CD34/ CB cells were cultured in stroma-
free liquid cultures with FL and TPO, alone or combined, LTC, totipotent stem cells were present, we sought to find
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Fig 1. (A) Nonadherent cell
expansion from CD34" CB cells.
Two thousand CB cells in 1 mL
were plated in quadruplicate 24-
well plates on day 0. Cells were
cultured in stroma-free in LTC
medium in the presence of FL,
KL, IL-3, and IL-6 alone or com-
bined. Every week half the cul-
ture volume was removed from
cell culture and the cells were
counted. The mean fold increase
over cell number plated on day
0 is shown at each time point of
LTC. Mean Ô SEM from three
separate experiments performed
in quadruplicate. (B) CFU-GM
expansion from CD34" CB cells
in stroma-free LTC. Two thou-
sand CD34" CB cells were plated
in quadruplicate 24-well plates
in the presence of the factors re-
ported above. The content of
CFU-GM of each well was estab-
lished at the beginning of the
LTC by agar assays. Every week
all the wells were demidepopu-
lated by removal of one half the
culture volume, which was re-
placed with freshly medium and
growth factors. Cells of the har-
vested media were counted and
suitable aliquots of the cell sus-
pension were assayed for CFU-
GM in quadruplicate dishes. The
results represent the mean Ô
SEM of three separate experi-
ments performed in quadrupli-
cate. (m) IL-3 " FL; (n) IL-3 " KL;
(l) IL-3 " KL " FL; (h) IL-6 " FL
" KL; (j) KL " FL.
out whether T and B cells had been generated. At the begin- LDA by plating from 1 to 1,000 CD34/ cells onto preestab-
lished irradiated feeder layers from normal BM and thenning of the cultures, the frequency of T and B cells in the
CD34/ cell population was very low. After several weeks assessing the number of CFC present 5 weeks later.
After 2 weeks of liquid culture, the LTC-IC content, deter-of liquid culture, T and B cells were barely detectable (CD2/
and CD19/ cells represented, respectively, 0.2% and mined by LDA as for input LTC-IC by evaluating the number
of CFC generated after 5 additional weeks in the standard BM0.012%). However, after incubation for an additional 14 days
in the presence of IL-7, IL-12, and FL, the percentage of stroma assay, was found to be 160-fold the input value. After
10 weeks of LTC, the LTC-IC number was 1,000-fold and byCD2/ cells ranged from 24.98% to 33.8% and CD19/ cells
ranged from 0.78% to 3.75% (Table 1). week 20 was over 200,000-fold the input value (Table 2).
CFU-BlLTC-IC Content and Amplification in Suspension Cultures
Primitive hematopoietic progenitors capable in vitro ofThe frequency of LTC-IC in the initial CD34/ CB cells
(input value) was 0.6% { 0.4%. This was determined by producing colonies composed of blast cells (CFU-Bl) have
AID Blood 0058 / 5h33$$1141 03-27-97 12:46:34 bldal WBS: Blood
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/89/8/2644/1410842/2644.pdf by guest on 02 April 2020
PIACIBELLO ET AL2648
Fig 2. Different stages of hematopoiesis in stroma-free LTC of CB
CD34" cells. (A) Expansion of hematopoietic cells in stroma-free cul-
tures stimulated by TPO (10 U/mL) alone (l), by FL (50 ng/mL) alone
(s), and by the combination of TPO (10 U/mL) " FL (50 ng/mL) (j).
The starting population was represented by 2 Ì 103 CD34" CB cells in
1 mL in 24-well plates. Fresh growth factors were added twice a week.
Cells were counted weekly from quadruplicate wells and the fold in-
crease was obtained by dividing the number of cells of each well
counted each week by the number of the starting population. Repre-
sented here is the mean Ô SEM of four different experiments (each
performed in quadruplicate). (B) Expansion of the CD34" (j) and the
CD34"CD38Ï (l) cell populations during LTC with FL " TPO. CB CD34"
cells were grown as described in Fig 1 for 25 weeks. Every 2 to 3 weeks
the cells harvested were stained with FITC- and PE-conjugated anti-
CD34 and anti-CD38 MoAb. The total number of each subpopulation
was obtained by multiplying the percentage of each subset by the
number of cells contained in each well. Results are expressed as the
fold increase (compared with the starting subpopulation) and repre-
sent the mean Ô SEM of analyses performed on quadruplicate wells
in four separate experiments. (h) CD34" cells in LTC grown in the
presence of FL alone. (s) CD34" cells in LTC grown in the presence of
TPO alone. (C) Production of hematopoietic progenitors in LTC in the
presence of FL " TPO. CD34" CB cells were grown for 25 weeks as
described in Fig 1. CFU-GM (j), CFU-MK (s), BFU-E (l), and CFU-
GEMM (h) were cultured as described in Fig 1. Results represent the
fold increase of each class of progenitors present in each well in deter-
mined periods of LTC, compared with the number of progenitors of
the beginning of the cultures. Mean Ô SEM of four wells per point in
four separate experiments.
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Table 1. Appearance of CD2" Cells After 12 Weeks of LTC
% CD2/ Cells % CD19/ Cells
Experiment /FL / IL-7 / /FL / IL-7 /
No. Untreated* IL-12 Untreated* IL-12
1 0.12 { 0.01 33.8 { 1.1 0.012 { 0 1.4 { 0.3
2 0.24 { 0.03 42.36 { 2.3 0.01 { 0 0.78 { 0.1
3 0.18 { 0.08 24.98 { 2.1 0.02 { 0 3.75 { 0.2
* CD34/ CB cells (21 103) were grown in stroma-free LTC containing
FL / TPO for 12 weeks and then were analyzed for CD2 and CD19
expression (untreated). Analogous replicate samples were incubated
for additional 14 to 21 days in the presence of 50 ng/mL FL, 100 U/
mL IL-7, and 100 U/mL IL-12. The cells were then harvested and ana-
lyzed for CD2 and CD19 expression. The results are the mean { SEM
of analyses performed in triplicate wells.
been described.13 These cells possess many features of stem
cells in that they are capable of self-renewal and also of
commitment towards a number of hematopoietic lineages.
In our hands, at the beginning of long-term suspension
cultures, 63% { 5.4% of the CFU-Bl were capable of gener-
ating secondary colonies after replating. Each blast colony
generated a mean of 5.6 { 1.2 secondary colonies. During
the LTC period, CFU-Bl underwent a progressive expansion
paralleling with that of other more mature committed pro-
genitors (Table 3). Thus, after 5 weeks of LTC, the CFU-
Bl colony number was 43-fold the input number and at week
20 reached 305,000-fold the number present in the initial
inoculum. In addition, expanded CFU-Bl still retained their
self-renewal capacity (or, at least, maintained the capacity
to differentiate toward multiple lineages). When the blast
cell colonies were replated in methylcellulose containing IL-
3 / IL-6, new blast cell colonies were generated, which, in
turn, were capable of generating tertiary colonies (data not
shown).
Analysis of the time course of CFC expansion showed
that the generation of CFU-GM did not show an entirely
linear progression (Fig 3A and B). Indeed, three to four
waves of colony generation were evident at certain time
points in all the experiments. The earliest peak was seen
around 5 weeks of culture and, since then, a peak was clearly
detectable every 4 to 5 weeks. The last peak occurred at
week 25 (Fig 3A). Overall, the picture seems to reflect a
production of clonogenic precursors from more and more
primitive stem cell subpopulations, which are driven into
proliferation after progressively longer periods of time. Al-
ternatively, it might also indicate that, during such a long
period of liquid culture, self-renewal of primitive stem cells
has occurred.
The colonies generated in semisolid assays, in identical
culture conditions, and in the presence of identical growth
factors, after several months of liquid culture, were much
larger (up to 1,000 cells), as if committed progenitors pos-
sessed an higher proliferative potential.
DISCUSSION
Our data demonstrate that the simple combination of two
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hematopoietic growth factors (FL and TPO), in the absence
of stromal cells, is capable of sustaining for more than 6
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Table 3. Progressive Expansion of CFU-Bl in LTCs weeks of liquid culture, still retains its capability to self-
renew and to generate colonies of cells belonging to granulo-Blast Cell Colonies
cyte-macrophage, erythroid, and megakaryocyte lineages
Weeks of % Recloning No. of Secondary Colonies/ and colonies of blast cells, which, in turn are capable of
LTC Fold Increase Efficiency* Blast Colony
tertiary replating. This represents an additional proof of the
0 1 63 { 5.4 5.6 { 1.2 capability of this culture system to sustain and expand also/3 9.24 { 0.6 55 { 2.6 5.2 { 0.4 primitive progenitors./5 43 { 2.7 ND ND So far, LTC systems capable to support human hematopoi-/8 421 { 11 ND ND
esis for extended periods of time, without exhaustion of/10 4,200 { 97 61 { 3.1 4.3 { 1.2
primitive stem cells, are all dependent on the presence of/12 5,407 { 145 ND ND
marrow stromal feeder layers.14,15,40,46,48 At the present time,/15 28,672 { 1,200 58 { 2.3 6 { 0.8
/18 65,556 { 2,406 ND ND the molecular mechanisms that mediate stromal cell-based
/20 305,420 { 12,400 53 { 4.6 6.7 { 1.2 stimulation of LTC-IC proliferation and differentiation are
not known. Previous studies showing the ability of immortal-Ability of FL / TPO to support CFU-Bl in LTC. CFU-Bl generated by
ized murine fibroblasts to substitute for human marrow1,000 CD34/ CB cells at the beginning of the LTC (time 0) and second-
ary colonies after replating (mean { SEM values from 3 separate feeder layers in human LTC-IC assays, including fibroblasts
experiments). Secondary clones comprised all types of colonies (GM, genetically unable to produce KL, have suggested that novel
G, erythroid, burst, and GEMM clones represented the total numbers growth factors may be involved.49 The possibility that FLT3
of colonies, respectively). ligand may play a role in this regard has emerged.22-24 More-
* The recloning efficiency is the percentage of colonies that gener- over, it has been recently reported that incubation of single
ates secondary colonies upon replating. Results represent the mean CD34/ CD380 BM cells in medium supplemented with FL,{ SEM of three separate experiments. KL, IL-3, IL-6, G-CSF, and nerve growth factor resulted in
the proliferation of initial cells to produce clones containing
LTC-IC. A 50-fold overall expansion in a 3- to 5-week timemonths both proliferation and renewal of CB primitive stem
frame was observed, indicating the ability of that cytokinecells, without any sign of their exhaustion.
mixture to stimulate primitive cells.39The progenitor cells and the cells produced in this system
The simple combination of the two growth factors usedpossess both antigenic and growth characteristics of all he-
here proved able to maintain for at least 6 months a verymatopoietic lineages, including those of T and B cells; thus,
large and continuously increasing production of hematopoi-the cells assayed during the extended period of LTC are
etic progenitors belonging to all lineages. This extremelylikely to represent primitive stem cells. The progressively
prolonged maintenance and the massive expansion of primi-higher and higher waves of CFU-C generation that can be
tive hematopoietic progenitors, including CFU-Bl and LTC-identified during the entire period of LTC suggest the pres-
IC, suggest that extensive renewal, with little differentiation,ence of numerous populations of primitive, deeply quiescent
takes place.stem cells, which begin to proliferate only after more and
FLT3 ligand was a likely candidate for supporting primi-more prolonged periods of time, well after that of the stan-
tive hematopoietic stem cell growth22-24; however, in ourdard LTC-ICs and the extended LTC-ICs (ELTC-ICs).48
assay, FL, by itself, was not sufficient to sustain long-termConsistent with the very prolonged and massive progenitor
hematopoiesis. Indeed, previous studies showed its abilityoutput, which is still expanding after 5 months of liquid
to act synergistically with more lineage-restricted growthculture (CFU-GM number after 25 weeks of LTC is over
factors and other early acting cytokines, such KL.37-41 In our6,000,000-fold the initial number), the LTC-IC number is
system, the association of FL with IL-3 or IL-6 resulted inalso in continuous expansion (after 20 weeks it is over
an impressive CFU-GM output that, on the other hand, was200,000-fold the input number).
not accompanied by maintenance of primitive stem cells.It has recently been shown that the CD34/ CD380 immu-
Also, TPO by itself proved unable to sustain long-termnophenotype defines a rare and primitive subpopulation of
hematopoiesis. Indeed, most studies initially suggested thathematopoietic progenitor cells in BM and CB enriched for
TPO was a lineage-restricted regulator with little or no activ-LTC-IC.46,47 Our starting population was composed of both
ity on nonmegakaryocitic lineages.25-29 Nevertheless, in pop-CD34/ CD38/ and CD34/ CD380 CB cells. It is possible
ulations of mouse fetal liver enriched for primitive hemato-that the early wave of CFU-C production is sustained by the
poietic cells, a significant proportion of cells express c-mpl.50CD34/ CD38/ population and that the later waves, after 8
Moreover, recent data suggest that, in combination withto 10 weeks of culture, are generated by the CD34/ CD380
EPO, TPO may augment growth of erythroid progenitors42subpopulation.
and cells of human nonmegakaryocitic leukemias can prolif-Besides the LTC-ICs, which reflect the presence of primi-
erate in response to TPO.51 An elevation of the number oftive, in vivo long-term repopulating stem cells, other assays
CFU-GEMM has also been observed upon TPO administra-have been used in this study to measure generation and
tion in monkeys.52 Finally, c-mpl–deficient mice displayedamplification of primitive stem cells. CFU-Bl12,13 possess
reduced total hematopoietic progenitor cell numbers, includ-many features of stem cells in that they are capable of self-
ing multipotential, blast, and committed progenitors of multi-renewal and also commitment toward a number of hemato-
ple lineages.43poietic lineages. In the LTC described here, the population
Thus, the simple combination of FL and TPO resulted toof CFU-Bl not only is maintained, but also is greatly ex-
panded. What is more, the expanded population, after several be both necessary and sufficient to sustain long-term stem
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Fig 3. Time course of CFU-GM expansion from CD34" CB cells. Two thousand CD34" cells were plated on day 0 in duplicate in 24 wells in
the presence of FL " TPO. Every week the content of CFU-GM per well was determined. The vertical axis represents the CFU-GM expansion
during 25 weeks of LTC. Two independent experiments of four are shown.
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